AMGN logo Amgen +
Amgen
+

Amgen (AMGN) Business News

Track Amgen in real time with a live news feed covering Amgen stock news, official press releases, company announcements, and an archive of historical Amgen news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead

24/7 Wall Street

9:03 AM | Tuesday | Sep 29, 2026

news photo
Loading...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Read full article redirect
9:03 AM | Tuesday | Sep 29, 2026

Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead

24/7 Wall Street

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Read full article arrow
News Thumbnail
10:15 AM | Monday | Sep 28, 2026

Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus

Zacks Investment Research

Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Sep 28, 2026

Should You Buy QQQ or VUG Right Now? Here's What History Suggests.

Fool - Investing News

It all comes down to portfolio construction -- one is logical, one isn't.

Read full article arrow
News Thumbnail
4:01 PM | Saturday | Sep 26, 2026

2 Healthcare Stocks That Just Delivered Great News for Investors

The Motley Fool

Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects.

Read full article arrow
News Thumbnail
10:31 AM | Friday | Sep 25, 2026

Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields

Zacks Investment Research

Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.

Read full article arrow
News Thumbnail
10:01 AM | Friday | Sep 25, 2026

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
11:58 AM | Thursday | Sep 24, 2026

How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding

247 Wallst

Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.

Read full article arrow
News Thumbnail
11:40 AM | Wednesday | Sep 23, 2026

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Zacks Investment Research

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Read full article arrow
News Thumbnail
9:01 AM | Tuesday | Sep 22, 2026

Amgen's autoimmune drug succeeds in late-stage trial

Reuters

Amgen said on Tuesday its experimental drug to treat an autoimmune ​disease that attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Sep 22, 2026

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

PRNewsWire

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity  Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease  THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

Read full article arrow
News Thumbnail